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ABSTRACT
In the context of traumatic brain injury (TBI), decompressive craniectomy (DC) is used as part of tiered
therapeutic protocols for patients with intracranial hypertension (secondary or protocol-driven DC). In add-
ition, the bone flap can be left out when evacuating a mass lesion, usually an acute subdural haematoma
(ASDH), in the acute phase (primary DC). Even though, the principle of ‘‘opening the skull’’ in order to con-
trol brain oedema and raised intracranial pressure has been practised since the beginning of the 20th cen-
tury, the last 20 years have been marked by efforts to develop the evidence base with the conduct of
randomised trials. This article discusses the merits and challenges of this approach and provides an over-
view of randomised trials of DC following TBI. An update on the RESCUEicp study, a randomised trial of DC
versus advanced medical management (including barbiturates) for severe and refractory post-traumatic
intracranial hypertension is provided. In addition, the rationale for the RESCUE-ASDH study, the first rando-
mised trial of primary DC versus craniotomy for adult head-injured patients with an ASDH, is presented.
ARTICLE HISTORY
Received 29 November 2015
Revised 19 January 2016
Accepted 21 February 2016
Published online 8 March
2016
KEYWORDS
Acute subdural haematoma;
brain oedema; clinical trial;
intracranial pressure;
traumatic brain injury
Introduction
Traumatic brain injury (TBI) remains a major public health prob-
lem across the globe.1 Intracranial pressure (ICP) following TBI
can be elevated due to increasing mass effect from haematomas
and contusions, diffuse brain swelling or hydrocephalus.
Intracranial hypertension can lead to ischemia due to reduction of
the cerebral perfusion pressure (CPP). Substantial evidence from
large cohort studies points to the fact that intracranial hyperten-
sion is associated with excess mortality following TBI.2,3
Decompressive craniectomy (DC) is a surgical procedure which
involves removal of a large part of the skull and opening of the
underlying dura mater. From a physiological viewpoint, DC helps
to overcome the rigid and non-compliant nature of the skull and
the dura mater, thereby leading to a reduction of the ICP.4
However, even though >100 years have passed since the first
description of DC by Theodor Kocher in the 20th century, uncer-
tainties still remain regarding the indications, optimal timing and
effects of DC on the functional outcome of head-injured patients.5
Definitions – primary and secondary DC
Primary DC refers to leaving a large part of the skull (bone flap)
out after evacuating an intracranial haematoma (mass lesion) in
the early phase after the head injury.5,6 Mass lesions can be extra-
dural, subdural, intraparenchymal or a combination thereof.7
However, the most frequent indication for a primary DC is an
acute subdural haematoma (ASDH).8–10 Typically, a large fronto–
temporo-parietal bone flap (hemi-craniectomy) is left out after
evacuating the haematoma either because the brain is bulging
beyond the inner table of the skull or because there is a concern
of increasing brain swelling (e.g. in a patient with contusions) in
the post-operative period.11,12
A DC may also be undertaken in head-injured patients who
are managed in an intensive care unit (ICU) with ICP monitoring.
This is usually referred to as a secondary DC.5,6 In this context, a
DC is performed as part of tiered therapeutic protocols which aim
to control raised ICP and ensure adequate CPP.13 The operation
can be undertaken as last-tier (life-saving) therapy when all other
measures have failed to reduce ICP at levels <25–35mmHg.
Alternatively, it can be performed as a second-tier therapy in
patients with less pronounced elevation of ICP (e.g. 20mmHg);
this can be viewed as a neuro-protective measure.5 Three main
options exist in terms of the site of a secondary DC: bifrontal
(bone flap extends from the floor of the anterior cranial fossa
anteriorly to the coronal suture posteriorly and to the middle cra-
nial fossa floor bilaterally), hemi-craniectomy (same as described
earlier) and bilateral hemi-craniectomy.
Decompressive craniectomy in the 20th century
The first modern report of the use of DC following TBI was pub-
lished by Harvey Cushing in 1908.14 Cushing treated head-injured
patients with a subtemporal DC and he reported a substantial
reduction in mortality. The period from the 1950s to 1970s was
marked by divided opinions regarding the utility of DC.5
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Proponents of DC were calling for controlled studies but the
opponents focused their criticism on the complications of DC and
the fact that patients surviving after a DC may be left in a severely
disabled or vegetative state. The management of TBI progressed
significantly in the 1980s and 1990s due to advances in neuroi-
maging (widespread introduction of CT scanning), prehospital
management, neurointensive care (widespread adoption of ICP
monitoring and tiered therapeutic protocols) and rehabilitation.
This led to a renaissance of interest in DC with many uncon-
trolled studies reporting a survival benefit with DC.15,16
Decompressive craniectomy in the 21st
century – developing the evidence base
The 21st century, so far, has seen consistent efforts to improve the
evidence base for DC following TBI with the conduct of rando-
mised trials (Figure 1). At this point, we need to consider what
evidence based medicine is and why it is necessary. Evidence
based medicine has been defined as ‘‘the conscientious, explicit
and judicious use of current best evidence in making decisions
about the care of individual patients’’.17 Sackett et al. have
described best available external clinical evidence as ‘‘clinically
relevant research, often from the basic sciences of medicine, but
especially from patient centred clinical research into the accuracy
and precision of diagnostic tests (including the clinical examin-
ation), the power of prognostic markers, and the efficacy and
safety of therapeutic, rehabilitative and preventive regimens’’.17 It
is desirable, but not always possible, for such evidence to be of
high quality, with good internal and external validity, low risk of
bias and reproducibility. The same authors have also suggested
that ‘‘external clinical evidence can inform, but can never replace,
individual clinical expertise, and it is this expertise that decides
whether the external evidence applies to the individual patient at
all and, if so, how it should be integrated into a clinical
decision’’.17
Experimental study designs can provide the evidence needed to
answer pertinent clinical questions. To study the efficacy of a
treatment, there needs to be a control group, ideally in the context
of a randomised controlled trial (RCT). In this setting the alloca-
tion of individuals to the treatment or control group occurs ran-
domly. Because of the random assignment the treatment and
control group are balanced, both in terms of observable and non-
observable characteristics. Therefore differences in the outcomes
between the two groups are attributed to the experimental effect
of exposure to the treatment. However, RCTs are sometimes not
feasible due to practical or ethical reasons. Moreover, RCTs are
not necessary for the evaluation of treatments with dramatic
effects that are unlikely to have resulted from inadequately con-
trolled biases. In addition, a number of factors, such as lack of
clinical equipoise, strong patient preferences, imbalance in surgical
expertise, poor compliance with allocated treatment (cross-over),
difficulty with blinding render trials of surgical interventions par-
ticularly challenging.18 Trials in severe TBI patients face a number
of additional complexities; clinical research in the emergency/ICU
setting is difficult, patients often lack the capacity to consent, care
of severe TBI is multifaceted and clinicians often have strong
views especially when comparing surgical with medical therapies.
In addition, new approaches, such as comparative effectiveness
research (CER) have gained traction in recent years. Non-
experimental CER studies – such as the CENTER-TBI project
(https://www.center-tbi.eu/) – aim to utilise the heterogeneity in
systems, practices and outcomes in order to compare the effective-
ness of interventions that are standard practice in some centres
but not in others.19 These efforts are extremely important and
promising and should be seen as being complementary to rando-
mised trials. Pragmatic RCTs – that aim to compare two or more
treatments in the ‘‘real-world’’ – are a form of CER, the so-called
experimental CER. We regard RCTs and non-experimental CER,
as two equally important facets of TBI research aiming to answer
questions regarding the clinical effectiveness of interventions. At
the same time, RCTs are widely accepted as the gold-standard
method for assessing the efficacy and effectiveness of therapeutic
interventions and, although difficult, surgical evaluation is achiev-
able and necessary. Hence, we believe that when a research
Figure 1. Randomised trials of decompressive craniectomy for TBI.
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question is sufficiently refined to allow the design of an RCT, one
should be undertaken if feasible.
BEST-TRIP trial
This study was a multi-centre randomised trial that included a
total of 324 patients with severe TBI treated in ICUs in Bolivia
and Ecuador.20 The study compared management guided by ICP
monitoring aiming to maintain ICP at or below 20mmHg with
management guided by clinical examination and serial computed
tomography (CT) imaging. Hence, it should be emphasised that
BEST-TRIP was not a trial of ICP monitoring and did not seek to
determine the efficacy of ICP monitoring. Even though a differ-
ence in the outcomes between the two arms was not found, since
the publication of the study, several editorials and study corres-
pondence have pointed out limitations in the trial design that
limit the external validity and generalisability of its findings.21,22
Importantly, patients in both arms received tiered ICP-lowering
therapies, and 30% of patients in each arm received a DC. The
BEST-TRIP trial, therefore, does not challenge the fundamental
concept that brain oedema and raised ICP should be actively
managed in patients with TBI.5
DECRA trial
The DECRA study was conducted between 2002 and 2010 in
Australia, New Zealand and Saudi Arabia.23 The study recruited
155 patients with severe diffuse TBI and moderate intracranial
hypertension. Patients were randomised within the first 72 h fol-
lowing TBI if their ICP exceeded 20mmHg for >15min – con-
tinuously or intermittently) within a 1-h period, and if they did
not respond to optimised first-tier ICP-lowering interventions.
The two arms of the trial were bifrontal DC and standard medical
management or standard medical management alone. Patients in
the surgical arm were found to have better ICP control, received
fewer interventions for raised ICP, and had a reduced length of
stay at the ICU. However, the investigators observed a higher rate
of unfavourable outcomes in surgical patients (70% versus 51%;
OR 2.21; 95% CI 1.14–4.26; p¼ 0.02). Nevertheless, 27% of
patients in the surgical arm had bilaterally unreactive pupils com-
pared with only 12% in the medical arm. A post hoc adjustment
for pupil reactivity at baseline, which was necessary as pupil
reactivity is known to be a major prognostic indicator of outcome
following TBI, revealed that the rate of unfavourable outcome was
not significantly different between the two arms (adjusted OR
1.90; 95% CI 0.95–3.79). Overall, the DECRA study provided con-
vincing evidence that early neuro-protective bifrontal DC is not
superior to medical management for patients with diffuse TBI.
RESCUEicp trial
In contrast to the DECRA study, the RESCUEicp trial is examin-
ing the effectiveness of DC (bifrontal or unilateral) as a last-tier
therapy for patients with severe, sustained and refractory post-
traumatic intracranial hypertension.24 Patients were randomised to
DC or continuing medical therapy if their ICP exceeds 25mmHg
for at least 1 h and is not responding to tiered ICP-lowering thera-
pies. A barbiturate infusion is not allowed pre-randomisation; it
only becomes an option for patients randomised in the medical
arm following randomisation. RESCUEicp is also a multi-centre
study but has a number of important differences from DECRA:
sample size (400 patients in RESCUEicp versus 155 patients in
DECRA); surgical technique (bifrontal or unilateral DC versus
bifrontal DC only); ICP threshold (25mmHg versus 20mmHg);
duration of refractory intracranial hypertension (at least 1 h versus
15min) and timing of randomisation (any time when inclusion
criteria are met versus within 72 h after TBI only).25 Enrolment of
new patients to the RESCUEicp trial ended on 31 March 2014
and the study is currently in follow-up.
The Statistical Analysis Plan (SAP) was agreed without refer-
ence to the unblinded data, approved by the independent chair of
the Trial Steering Committee and released in the public domain
in October 2015. The SAP can be found in the Supplementary
material. The results (primary endpoint) are expected in 2016.
RESCUE-ASDH trial
Two-thirds of TBI patients undergoing emergency neurosurgery
have an ASDH evacuated. These hematomas have been associated
with a high mortality rate and low rates of functional recovery.11
In addition, parenchymal injuries – such as contusions – and
brain swelling are often found in patients with ASDH.8 Miller
et al. reported that two-thirds of the 48 patients with an evacuated
ASDH had raised ICP in the post-operative period; increased ICP
was defined as persistent elevation of mean ICP >20mmHg dur-
ing the period of continuous monitoring of ICP in the ICU.26
Importantly, half of the patients with raised ICP developed uncon-
trollable intracranial hypertension leading to herniation and death.
Wilberger et al. observed that 40% of their cohort of 101 coma-
tose patients who underwent a craniotomy for an ASDH had an
ICP which remained <20mmHg in the post-operative period,
while 43% had a sustained period of uncontrollable intracranial
hypertension with ICP peaking >45mmHg.27 Importantly, the
authors observed that the mortality rate was 40% in the former
but close to 95% in the latter subgroup. These studies provide
convincing evidence that, firstly, ICP can be elevated after ASDH
evacuation and, secondly, elevated ICP leads to higher mortality.
In a retrospective cohort comparison study of 91 patients who
had an operation for an ASDH, 56% received a primary DC,
while the rest a craniotomy.10 The standardised morbidity ratio
was lower in patients who had a DC (0.75; 95% CI 0.51–1.07)
compared to those who had a craniotomy (0.90; 95% CI
0.57–1.35). Although the 95% confidence intervals overlap, this
study supports the hypothesis that a primary DC (i.e. bone flap
left out after ASDH evacuation) may lead to better outcomes com-
pared to a craniotomy (i.e. bone flap is replaced) due to better
control of brain swelling and intracranial hypertension in the
post-operative period. This hypothesis is also supported by a
recently published two-centre non-experimental CER study, which
found that post-operative ICP was better controlled and patient
outcomes were better in the centre with greater utilisation of pri-
mary DC.9
However, there is a paucity of high-quality evidence in the lit-
erature regarding the best surgical strategy (primary DC or crani-
otomy) for this group of patients and surgical decision making is
often haphazard.28 In a survey of UK surgeons, a significant vari-
ation in the surgical management of ASDH was observed with
41% of the respondents using primary DC <25% of the time but
approximately one-third using DC in >50% of such cases.29
On this background, the RESCUE-ASDH study was funded by
the UK National Institute for Health Research (NIHR) as a multi-
centre, pragmatic, parallel group randomised trial that aims to
compare the clinical and cost-effectiveness of primary DC versus
craniotomy for the management of adult head-injured patients
undergoing evacuation of an ASDH. The trial was designed as a
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collaborative effort involving members of the British
Neurosurgical Trainee Research Collaborative (BNTRC; www.
bntrc.org.uk) and British Neurotrauma Group (BNTG; www.
ukneurotrauma.org.uk), clinicians and academics with an interest
in TBI, members of the Cambridge Clinical Trials Unit, health
economists and service user representatives.
The criteria which are being used to determine eligibility of
individual patients are:
 Inclusion criteria:
 Adult head-injured patients (>16 years)
 ASDH on CT*
 The admitting neurosurgeon feels that the haema-
toma needs to be evacuated either by a craniotomy
or DC (bone flap at least 11 cm in both instances)*
* Patients with additional lesions (e.g. intracerebral haemor-
rhage, contusions) can be included
 Exclusion criteria:
 Bilateral ASDHs both requiring evacuation
 Previous enrolment in RESCUE-ASDH study
 Severe pre-existing physical or mental disability or severe
co-morbidity which would lead to a poor outcome even if
the patient made a full recovery from the head injury.
Eligible patients are randomised to craniotomy or DC intra-
operatively after evacuating the ASDH. Patients with significant
brain swelling preventing safe replacement of the bone flap are
not suitable for randomisation and are being followed-up in the
context of an observational cohort.
The primary outcome measure is the extended Glasgow
Outcome Scale (GOSE) at 12-month post-injury (Table 1).
The secondary outcome measures are:
 GOSE at 6 months
 quality of life (EQ-5D) at discharge from neurosurgical
ward, 6 and 12 months
 Glasgow Coma Scale (GCS) on discharge from the inten-
sive care unit (ICU) and from neurosurgical ward
 length of stay in ICU, neurosurgical and rehabilitation
unit
 discharge destination from acute neurosurgical ward
 serious adverse events and surgical complications
 subsequent complications/re-admissions within the 1-year
follow-up period
 return to operating theatre for cranial surgery within
2 weeks after randomisation
 incidence of hydrocephalus
 therapy intensity level in the post-intervention period
 economic evaluation
Analysis will be performed on an ‘‘intention-to-treat’’ basis
with a proportional odds model adjusted for covariates.
Retrospective studies suggest a favourable outcome (moderate dis-
ability or good recovery) in 35% of patients undergoing evacu-
ation of ASDH.11 The sample size of 990 patients (495 in each
arm; 10% drop out rate) will allow us to detect the equivalent of
an 8% absolute difference in favourable outcome [90% power and
two-sided significance 0.05 (35% versus 43%)]. This corresponds
to the equivalent of an 8% treatment effect.
The internal pilot phase of the study started in UK in autumn
2014. We are now just over 1 year since recruitment started and
the study has achieved the following milestones (as of 29th
November 2015):
 64 patients have been randomised from 15 UK sites.
 57 patients have been enrolled in the observational study
cohort.
 21 centres are now open to recruitment in UK and 2
more in set up.
Clinicians interested to collaborate are encouraged to visit
http://www.rescueasdh.org/contact-us for further information.
Conclusions
The 21st century has been marked by efforts to develop the evi-
dence base for DC following TBI. Current evidence suggests that
early (neuroprotective) bifrontal DC is not superior to medical
management for patients with diffuse TBI. Secondary DC as a
last-tier therapy for severe and refractory post-traumatic intracra-
nial hypertension is the subject of the RESCUEicp study, while
primary DC for patients with ASDH is being systematically eval-
uated in the context of the RESCUE-ASDH trial. In view of the
currently available evidence, and owing to the number of potential
complications with DC, indiscriminate use of DC for patients with
TBI is not appropriate.
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Table 1. The eight categories of the
extended Glasgow Outcome Scale (GOSE).
Score Category
1 Death
2 Vegetative state
3 Lower severe disability
4 Upper severe disability
5 Lower moderate disability
6 Upper moderate disability
7 Lower good recovery
8 Upper good recovery
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